Action of Colchicine and Cytochalasin B on the Acetylcholine Receptor

Anwyl, Roger; Narahashi, Toshio

doi:10.1111/j.1476-5381.1979.tb07855.x

Cited by 7 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The half-life of the drugs is short, which, after their i.p. or intravenous administration, are distributed in various organs within 15–180 min for CB and 60 min for BFA followed by a gradual reduction until their complete elimination after 24 h [ 46 ].…”

Section: Methodsmentioning

confidence: 99%

Brefeldin A and Cytochalasin B reduce dengue virus replication in cell cultures but do not protect mice against viral challenge

Farias

Machado

Júnior

et al. 2019

Access Microbiology

View full text Add to dashboard Cite

Background Dengue is an emerging arboviral disease caused by dengue virus (DENV). DENV belongs to the family Flaviviridae and genus Flavivirus . No specific anti-DENV drugs are currently available. Methods We investigated the antiviral activity of Brefeldin A (BFA) and Cytochalasin B (CB) against this infection. The drugs BFA and CB were used in the in vitro treatment of dengue-2 virus (DENV-2) infections in Vero cell cultures and in protection from lethality by post-challenge administration in Swiss mice. Viral load was quantified by qRT-PCR and plaque assay in Vero cell cultures, post-infection, treated or not with the drugs. Post-challenge drug levels were evaluated by survival analysis. Results Our results indicate that doses of 5 µg ml −1 of BFA and 10 µg ml −1 of CB are not toxic to the cells and induce a statistically significant inhibition of DENV-2 replication in Vero cells when compared to control. No BFA- or CB-treated mice survived the challenge with DENV-2. Conclusion These data suggest that BFA and CB have an antiviral action against DENV-2 replication in Vero cell culture, but do not alter infected mice mortality.

show abstract

Section: Methodsmentioning

confidence: 99%